U.S. RESEARCH ROUNDUP-Duolingo, Nova, Universal Health Services Aug 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Duolingo, Nova and Universal Health Services, on Friday. HIGHLIGHTS * Duolingo Inc DUOL.O : Goldman Sachs raises to neutral from sell * Eventbrite Inc EB.N : Piper Sandler cuts to neutral from overweight * HCA Healthcare Inc HCA.N : JP Morgan raises target price to $379 from $332 * Nova Ltd NVMI.O : E

U.S. RESEARCH ROUNDUP-Amphastar Pharmaceuticals, G1 Therapeutics, Upwork Aug 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amphastar Pharmaceuticals, G1 Therapeutics and Upwork on Thursday. HIGHLIGHTS * Amphastar Pharmaceuticals Inc AMPH.O : Piper Sandler cuts target price to $66 from $71 * Charles River Laboratories International Inc CRL.N : Baird cuts to neutral * G1 Therapeutics Inc GTHX.O : H.C.

U.S. RESEARCH ROUNDUP-Amgen, Atkore, MoneyLion Aug 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amgen, Atkore and MoneyLion on Wednesday. HIGHLIGHTS * Amgen Inc AMGN.O : RBC raises target price to $362 from $332 * Atkore Inc ATKR.N : RBC cuts to sector perform from outperform * MoneyLion ML.N : Needham cuts target price to $70 from $100 * Progyny Inc PGNY.O : BTIG cuts to neutral from buy * Truecar Inc TRUE.O :

BRIEF-Acadia Pharmaceuticals Q2 EPS USD 0.2 Vs. IBES Estimate USD 0.18 Aug 06 (Reuters) - Acadia Pharmaceuticals Q2 product sales USD 241.963 million vs. IBES estimate USD 235.4 million. Q2 pretax profit USD 37.182 million vs. IBES estimate USD 32.1 million Q2 net income USD 33.389 million vs. IBES estimate USD 31.1 million Q2 operating expenses US

ACADIA Pharmaceuticals Inc expected to post earnings of 18 cents a share - Earnings Preview ACADIA Pharmaceuticals Inc ACAD.OQ ACAD.O is expected to show a rise in quarterly revenue when it reports results on August 6 for the period ending June 30 2024 The San Diego California-based company is expected to report a 42.5% increase in revenue to $235.418 million from $165.24 million a year ago, according to the mean estimate from 18 analysts, based on LSEG data.